W D Figg

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint The Pharm.D. investigator in clinical pharmacology: supply and demand
    W D Figg
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Pharmacol Ther 84:526-9. 2008
  2. pmc Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
    N F Smith
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Br J Cancer 98:1630-2. 2008
  3. pmc A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
    Bevin C English
    Molecular Pharmacology Section
    Ther Clin Risk Manag 6:579-83. 2010
  4. pmc Expression of OATP family members in hormone-related cancers: potential markers of progression
    Heather Pressler
    Molecular Pharmacology Section, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 6:e20372. 2011
  5. pmc Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
    Xuan Huang
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Hematol Oncol 5:35. 2012
  6. pmc Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis
    Sarah M Troutman
    Molecular Pharmacology Section, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncologist 17:312-20. 2012
  7. pmc Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
    Erin R Gardner
    Clinical Pharmacology Program, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
    J Exp Clin Cancer Res 28:99. 2009
  8. pmc Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
    Lokesh Jain
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Exp Clin Cancer Res 29:95. 2010
  9. pmc Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
    Ilaria Pastina
    Department of Medical Oncology, Pisa University Hospital, Pisa, Italy
    BMC Cancer 10:511. 2010
  10. pmc A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer
    William D Figg
    Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 183:2219-26. 2010

Collaborators

Detail Information

Publications133 found, 100 shown here

  1. ncbi request reprint The Pharm.D. investigator in clinical pharmacology: supply and demand
    W D Figg
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Clin Pharmacol Ther 84:526-9. 2008
    ..This expanded understanding is important as we start to address the overwhelming mandate and the unfortunate shortage of qualified investigators in the field (both physicians and non-physicians)...
  2. pmc Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
    N F Smith
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Br J Cancer 98:1630-2. 2008
    ..This study illustrates the potential of BAS 100 to increase the low and variable oral bioavailability of erlotinib in cancer patients...
  3. pmc A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
    Bevin C English
    Molecular Pharmacology Section
    Ther Clin Risk Manag 6:579-83. 2010
    ..More studies are needed to identify genetic risk factors that may predict the development of this important clinical condition...
  4. pmc Expression of OATP family members in hormone-related cancers: potential markers of progression
    Heather Pressler
    Molecular Pharmacology Section, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 6:e20372. 2011
    ..OATPs correlate to differentiation in certain hormone-dependent cancers, thus may be useful as biomarkers for assessing clinical treatment and stage of disease...
  5. pmc Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
    Xuan Huang
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Hematol Oncol 5:35. 2012
    ....
  6. pmc Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis
    Sarah M Troutman
    Molecular Pharmacology Section, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncologist 17:312-20. 2012
    ..Though several studies have demonstrated an association between certain 8q24 SNPs and clinicopathological features of the disease, review of this topic revealed conflicting results...
  7. pmc Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
    Erin R Gardner
    Clinical Pharmacology Program, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
    J Exp Clin Cancer Res 28:99. 2009
    ..The effect of inhibiting these transporters on tissue exposure to imatinib remains unclear...
  8. pmc Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
    Lokesh Jain
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Exp Clin Cancer Res 29:95. 2010
    ..We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes...
  9. pmc Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
    Ilaria Pastina
    Department of Medical Oncology, Pisa University Hospital, Pisa, Italy
    BMC Cancer 10:511. 2010
    ..Functional polymorphisms within the cytochrome P450 1B1 (CYP1B1) gene have been associated with alterations in enzymatic expression and activity and may change sensitivity to the widely used docetaxel regimen...
  10. pmc A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer
    William D Figg
    Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 183:2219-26. 2010
    ....
  11. doi request reprint Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research
    William D Figg
    National Cancer Institute, Bethesda, Maryland, USA
    Pharmacotherapy 28:821-33. 2008
    ..This report also puts forth recommendations for educating future pharmaceutical scientists...
  12. ncbi request reprint A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases
    William D Figg
    Center for Cancer Research, National Cancer Institute, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 173:790-6. 2005
    ..The pharmacokinetics of KT and AL were characterized and changes in circulating angiogenic factors were assessed...
  13. ncbi request reprint A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
    W D Figg
    Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:1888-93. 2001
    ..Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize. Based on those data, we initiated a Phase II trial of thalidomide in patients with metastatic androgen-independent prostate cancer...
  14. ncbi request reprint Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer
    William D Figg
    Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Cancer Therapy and Evaluation Program, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    BJU Int 99:1047-55. 2007
    ....
  15. ncbi request reprint Prostate cancer - 6th International Congress
    William D Figg
    Molecular Pharmacology Section, Cancer Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    IDrugs 9:675-8. 2006
  16. ncbi request reprint Pharmacokinetics of thalidomide in an elderly prostate cancer population
    W D Figg
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    J Pharm Sci 88:121-5. 1999
    ..A dose-proportional increase in thalidomide steady-state concentrations was seen after multiple daily dosing of thalidomide...
  17. pmc Disclosing a diagnosis of cancer: where and how does it occur?
    William D Figg
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 28:3630-5. 2010
    ..We examined how cancer diagnoses were first given to patients and the impact of different aspects of disclosure on patient satisfaction...
  18. ncbi request reprint Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics
    William D Figg
    Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 5:840-1. 2006
  19. ncbi request reprint Scientific collaboration results in higher citation rates of published articles
    William D Figg
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:759-67. 2006
    ..The secondary objective was to analyze the relationship between the number of authors/article and the number of institutions/article for the period of study...
  20. ncbi request reprint The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer
    William D Figg
    Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Clin Pharmacol Ther 79:1-8. 2006
  21. ncbi request reprint Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
    M A Rudek
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 19:584-92. 2001
    ..042). CONCLUSION: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials...
  22. ncbi request reprint Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
    N A Dawson
    Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 15:1470-7. 1997
    ..To assess the efficacy and toxicity of suramin, hydrocortisone, leuprolide, and flutamide in previously untreated metastatic prostate cancer...
  23. ncbi request reprint A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction
    E C Kohn
    Medicine Branch, National Cancer Institute, and Warren G Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:1600-9. 2001
    ..Preclinical and clinical investigation of the combination of the antiangiogenesis/anti-invasion agent carboxyamido-triazole (CAI) administered with the cytotoxic agent paclitaxel (PAX)...
  24. ncbi request reprint Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models
    E A Sausville
    DTP Clinical Trials Unit, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
    Cancer Chemother Pharmacol 42:S54-9. 1998
    ..Specific binding to human alpha1-acidic glycoprotein has been demonstrated. These findings reinforce the need to consider actual clinical pharmacology data in "real time" with phase I studies...
  25. ncbi request reprint Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines
    M V Blagosklonny
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bldg 10, 12N226, Bethesda, MD 20892, USA
    Int J Oncol 18:697-704. 2001
    ..2 nM) and UCN-01. In PrEC, UCN-01 downregulated cyclin D1 and arrest growth with an IC50 less than 100 nM. We conclude that loss of sensitivity to either UCN-01 or PMA accompanies progression of prostate cancer...
  26. ncbi request reprint A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)
    S Bates
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 92:1577-90. 2001
    ..The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day continuous infusion...
  27. ncbi request reprint Reversal of multidrug resistance: lessons from clinical oncology
    Susan F Bates
    Molecular Therapeutics Section, Medicine Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Novartis Found Symp 243:83-96; discussion 96-102, 180-5. 2002
    ..Using third generation Pgp antagonists and properly designed clinical trials, it should be possible to determine the contribution of modulators to the reversal of clinical drug resistance...
  28. ncbi request reprint Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
    A M Senderowicz
    Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 16:2986-99. 1998
    ....
  29. ncbi request reprint Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
    E A Sausville
    Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, and Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20852, USA
    J Clin Oncol 19:2319-33. 2001
    ..To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-hour continuous intravenous infusion (CIV)...
  30. ncbi request reprint Suramin administration is associated with a decrease in serum calcium levels
    M M Walther
    Urologic Oncology Branch, DCS NCI NIH, Bethesda, MD 20892 1501, USA
    World J Urol 18:388-91. 2000
    ..Suramin placed in calcium controls did not affect calcium determination using three commercially available methods...
  31. ncbi request reprint Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833
    I Chico
    Medicine Branch and Department of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutesof Health, Bethesda, MD 20892, USA
    J Clin Oncol 19:832-42. 2001
    ..Future development of combinations such as this should include strategies to predict pharmacokinetics of the chemotherapeutic agent. This in turn will facilitate dosing to achieve comparable CPss and AUCs...
  32. ncbi request reprint A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
    W D Figg
    Medicine Branch, Division of Clinical Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Oncol 28:62-6. 2001
    ..Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management...
  33. ncbi request reprint Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms
    H R Alexander
    Surgical Metabolism Section, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 4:2357-62. 1998
    ..These data indicate that TNF must continue to be critically evaluated in clinical trials before it is routinely used with melphalan in isolated organ perfusion...
  34. pmc Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor
    J Horti
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    Br J Cancer 79:1588-93. 1999
    ..Increased AR transcription was also reflected at the protein level. In conclusion, TNP-470 and AGM-1883 both up-regulated PSA making clinical utilization of this surrogate marker problematic...
  35. ncbi request reprint Thalidomide neuropathy in patients treated for metastatic prostate cancer
    F M Molloy
    EMG Section, National Institute of Neurological Disorders and Stroke (NINDS, 10 Center Drive, MSC 1404, Bethesda, Maryland 20892-1404, USA
    Muscle Nerve 24:1050-7. 2001
    ..Older age and cumulative dose were possible contributing factors. Neuropathy may thus be a common complication of thalidomide in older patients. The SNAP index can be used to monitor peripheral neuropathy, but not for early detection...
  36. ncbi request reprint Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations
    E C Kohn
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 15:1985-93. 1997
    ..An encapsulated micronized powder formulation has been developed to optimize CAI administration. A phase I dose escalation trial with pharmacokinetic analysis has been performed...
  37. ncbi request reprint Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
    Qin C Ryan
    Clinical Trials Unit, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:3912-22. 2005
    ..The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275...
  38. ncbi request reprint Effect of ABCG2 genotype on the oral bioavailability of topotecan
    Alex Sparreboom
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:650-8. 2005
    ..0% versus 31.4%; p = 0.037). It is suggested that the high frequency of the A allele in certain ethnic groups may have therapeutic implications for individuals treated with topotecan or other ABCG2 substrates...
  39. ncbi request reprint National Cancer Institute intramural approach to advanced prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Prostate Cancer 1:153-62. 2002
    ....
  40. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
    ..These results suggest that definitive clinical trials combining antiangiogenic agent combinations with docetaxel are warranted to improve treatment outcomes for patients with metastatic CRPC...
  41. doi request reprint Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
    Nilofer S Azad
    Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 26:3709-14. 2008
    ..Bevacizumab is a monoclonal antibody targeted against VEGF. We hypothesized that the complementary inhibition of VEGF signaling would have synergistic therapeutic effects...
  42. pmc Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer
    R C Bergan
    Department of Cell and Cancer Biology, National Cancer Institute, Bethesda, Maryland, USA
    J Natl Med Assoc 89:622-8. 1997
    ..These findings are consistent with the hypothesis that therapies that work through mechanisms independent of the androgen receptor may result in similar outcomes across ethnic groups...
  43. ncbi request reprint Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay
    E A Kruger
    Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:1867-72. 2001
    ..We conclude that assays such as the human serum rat aortic ring bioassay may prove useful in predicting the concentrations of protein-bound antiangiogenic agents required for free fraction biological activity...
  44. ncbi request reprint A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
    R A Messmann
    Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 6:1302-13. 2000
    ....
  45. ncbi request reprint Reversible sideroblastic anemia associated with the tetracycline analogue COL-3
    M A Rudek
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Hematol 67:51-3. 2001
    ..Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51-53, 2001. Published 2001 Wiley-Liss, Inc...
  46. pmc A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
    William D Figg
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Urol 181:1104-13; discussion 1113. 2009
    ..We determined whether thalidomide can prolong progression-free survival in men with biochemically recurrent prostate cancer treated with limited androgen deprivation therapy...
  47. pmc Angiogenesis inhibitors in the treatment of prostate cancer
    Paul G Kluetz
    National Cancer Institute, Medical Oncology Branch, Building 10, Room 12N226, 9000 Rockville Pike Bethesda, MD 20892, USA
    Expert Opin Pharmacother 11:233-47. 2010
    ..S. men. The efficacy of docetaxel and prednisone in metastatic castrate-resistant prostate cancer (mCRPC) has been shown to improve overall survival; however, its effect is not durable, highlighting the need for new therapies...
  48. ncbi request reprint Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer
    D L Bartlett
    Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 129:176-87. 2001
    ..HAI appears to prolong the duration of response after IHP, and this combined treatment strategy deserves additional clinical evaluation as a therapeutic modality in this setting...
  49. ncbi request reprint The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel
    M H Kang
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:1610-7. 2001
    ..CONCLUSIONS: PSC 833 increases the plasma concentration of 6alpha-hydroxypaclitaxel during paclitaxel therapy. Inhibition of cytochrome P-450 3A4 by PSC 833 may explain this in part, although other mechanisms cannot be excluded...
  50. ncbi request reprint A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer
    A Thibault
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Tumori 84:87-9. 1998
    ..CONCLUSIONS: We conclude that decitabine is a well tolerated regimen with modest clinical activity against hormone-independent prostate cancer. Further investigations in patients of African-American origin may be warranted...
  51. ncbi request reprint Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Antoinette R Tan
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 10:5038-47. 2004
    ..The purpose of this study was to determine the toxicities and characterize the pharmacokinetics of docetaxel and flavopiridol in patients with metastatic breast cancer...
  52. ncbi request reprint Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel
    Michael C Cox
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 12:4636-40. 2006
    ..This study examines the influence of garlic supplementation on the pharmacokinetics of docetaxel, a CYP3A4 substrate...
  53. pmc Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies
    James F Pingpank
    Surgical Metabolism Section, Surgery Branch, National Cancer Institute National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Clin Oncol 23:3465-74. 2005
    ..The purpose of the study was to demonstrate feasibility in an initial cohort and subsequently determine the maximum tolerated dose and dose-limiting toxicity of melphalan...
  54. ncbi request reprint Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
    William L Dahut
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 22:2532-9. 2004
    ..Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC...
  55. ncbi request reprint A phase II study of perifosine in androgen independent prostate cancer
    Edwin M Posadas
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:1133-7. 2005
    ..The primary objective of this study was to determine the clinical efficacy of this agent in the treatment of androgen-independent prostate cancer (AIPC) using PSA and clinical criteria...
  56. ncbi request reprint Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
    Milin R Acharya
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
    Invest New Drugs 24:367-75. 2006
    ..To evaluate elimination pathways of the histone deacetylase inhibitor MS-275 in vitro and screen for relationships between demographic factors that may affect its pharmacokinetics in vivo...
  57. pmc A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer
    Nima Sharifi
    Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
    BJU Int 102:617-21. 2008
    ....
  58. pmc ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
    Tristan M Sissung
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4543-9. 2008
    ..Polymorphisms that are associated with ABCB1 expression and function may be linked to treatment efficacy and the development of neutropenia and neurotoxicity in patients with androgen-independent prostate cancer receiving docetaxel...
  59. ncbi request reprint Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms
    Suoping Zhai
    Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Anticancer Drugs 14:125-35. 2003
    ..The pharmacogenetic analyses did not support that the UGT1A1 promoter polymorphism could affect flavopiridol pharmacokinetics and alter the incidence and severity of diarrhea induced by the drug...
  60. ncbi request reprint Suramin's development: what did we learn?
    Maninderjeet Kaur
    Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    Invest New Drugs 20:209-19. 2002
    ..These lessons can be applied to all clinical trials in hormone refractory prostate cancer. Suramin has significantly enhanced the evolution of our knowledge in several areas of prostate cancer biology and treatment...
  61. ncbi request reprint Drug-induced lupus associated with COL-3: report of 3 cases
    J V Ghate
    Dermatology Branch, National Institutes of Health, Bldg 10, Room 12N238, Bethesda, MD 20892-1908, USA
    Arch Dermatol 137:471-4. 2001
    ..The rapid onset and the phototoxic appearance of the accompanying eruptions might suggest that damage to the keratinocytes caused the formation of neoantigens to which autoantibodies formed...
  62. ncbi request reprint The androgen receptor gene and its influence on the development and progression of prostate cancer
    J S Montgomery
    Cancer Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA
    J Pathol 195:138-46. 2001
    ..Further study of the function of the androgen receptor will offer a better understanding of prostate cancer pathogenesis and progression, aiding the development of more effective treatments for this disease...
  63. ncbi request reprint Phenylacetate pharmacokinetics based on iterative two-stage population analysis
    A H Burstein
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA
    Pharmacotherapy 21:281-6. 2001
    ..06, 1.66), and 0.0038 (0.0019, 0.0058) hour(-1), respectively. CONCLUSION: The results of this study are similar to previous pharmacokinetic evaluations using the Abbottbase PKS system but suggest that earlier analyses were suboptimal...
  64. ncbi request reprint Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model
    Haiqing Li
    Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    BJU Int 101:884-8. 2008
    ....
  65. ncbi request reprint Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone
    Shenhong L Wu
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    BJU Int 99:525-8. 2007
    ....
  66. ncbi request reprint Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer
    Jeanny B Aragon-Ching
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bathesda, MD, USA
    BJU Int 100:1245-8. 2007
    ..To assess the significance of viable tumour in the prostate of patients with metastatic androgen-independent prostate cancer (AIPC)...
  67. ncbi request reprint Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
    Cliona Grant
    Medical Oncology Branch, SAIC Frederick, NCI Frederick, MA, USA
    Expert Rev Anticancer Ther 10:997-1008. 2010
    ....
  68. pmc A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors
    Nilofer Azad
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Cancer Biol Ther 8:1800-5. 2009
    ..We hypothesized daily oral micronized CAI with q3 week paclitaxel would be well-tolerated and active...
  69. ncbi request reprint Pharmacogenetics of irinotecan metabolism and transport: an update
    Nicola F Smith
    Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Toxicol In Vitro 20:163-75. 2006
    ..This report provides an update on current strategies to individualize irinotecan chemotherapy based on each patient's genetic constitution, which may ultimately lead to more selective use of this agent...
  70. ncbi request reprint Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
    Suoping Zhai
    Center for Cancer Research, National Cancer Institute, Building 10 Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Ann Pharmacother 36:905-11. 2002
    ..To review preclinical and clinical information on flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs), tested as an antitumor agent...
  71. ncbi request reprint Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
    Antoinette R Tan
    Center for Cancer Research, Developmental Therapeutics Program, and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 20:4074-82. 2002
    ..To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as a daily 1-hour infusion every 3 weeks...
  72. ncbi request reprint Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice
    Sylvia S W Ng
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:4192-7. 2004
    ..The current study evaluated the therapeutic potential of these analogs in the treatment of prostate cancer in vivo...
  73. ncbi request reprint Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay
    Gordon R Macpherson
    Molecular Pharmacology Laboratory, Laboratory of Receptor Biology and Gene Expression, and Cell and Cancer Biology Branch and Vascular Biology Faculty, National Cancer Institute, Bethesda, MD 20892, USA
    Mol Cancer Ther 2:845-54. 2003
    ..In view of this in vitro data, we suggest that clinical trials involving endostatin treatment of late-stage disease may not adequately represent the efficacy of this drug in early-stage cancer...
  74. ncbi request reprint Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide
    Yuichi Ando
    Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 1:669-73. 2002
    ..Although this study had no power to detect the statistical significance of the CYP2C19 genotype, the findings were consistent with our hypothesis. The role of CYP2C19 polymorphism in thalidomide treatments remains to be elucidated...
  75. ncbi request reprint The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer
    Avi S Retter
    Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, 12N226, Bethesda, MD 20892, USA
    Clin Prostate Cancer 2:153-9. 2003
    ..This article will review the background of angiogenesis inhibition and the use of such combinations in metastatic prostate cancer...
  76. ncbi request reprint Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
    Nicola F Smith
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 4:815-8. 2005
    ..These data suggest that OATP1B3 is a key regulator of hepatic uptake, and may therefore play a role in the variable response to treatment with taxanes...
  77. ncbi request reprint Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics
    N F Smith
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Pharmacol Ther 81:76-82. 2007
    ..3). The studied SNPs in SLCO1B3 appear to play a limited role in the disposition of paclitaxel, although their clinical significance in other ethnic populations remains to be investigated...
  78. ncbi request reprint Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer
    J B Sunwoo
    Head and Neck Surgery Branch, National Institute of Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 19:800-11. 2001
    ..CONCLUSION: Paclitaxel administered as a 120-hour continuous infusion in combination with radiotherapy is a feasible and promising treatment for patients with advanced HNSCC...
  79. ncbi request reprint Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning
    J A Carrasquillo
    Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1180, USA
    J Nucl Med 42:1359-63. 2001
    ..Use of alendronate before bone scanning is unlikely to result in decreased detection of lesions or falsely decreased 99mTc-MDP activity at metastatic bone tumor sites...
  80. ncbi request reprint Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
    Shivaani Kummar
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:5411-7. 2007
    ..The aims of this phase I trial were to determine the dose-limiting toxicities and maximum tolerated dose of oral MS-275 in humans administered with food on a once weekly schedule and to study the pharmacokinetics of oral MS-275...
  81. ncbi request reprint Androgen receptor modulation: lessons learned from beyond the prostate
    Nima Sharifi
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 6:1358-9. 2007
    ..Here, we examine recent findings from the description of a compound that degrades AR and induces dissociation of AR from an AR coactivator. The biochemistry of this compound may have implications for prostate cancer...
  82. doi request reprint Pharmacogenetics of membrane transporters: an update on current approaches
    Tristan M Sissung
    Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Mol Biotechnol 44:152-67. 2010
    ..A comprehensive list of substrates for the major drug transporters is included. Finally, studies linking transporter genotype with clinical outcomes are discussed...
  83. ncbi request reprint A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors
    Howard A Fine
    Neuro Oncology Branch and Medical Oncology Branch, National Cancer Institute, The National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:7101-6. 2007
    ....
  84. pmc A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:383-9. 2010
    ..We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advanced malignancies...
  85. pmc Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    Susan E Bates
    Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 148:256-67. 2010
    ....
  86. ncbi request reprint Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry
    Kyunghwa Hwang
    Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 804:289-94. 2004
    ..The values for precision and accuracy were always < or =5.58 and <11.4% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of MS-275 in a cancer patient...
  87. pmc Reversal of docetaxel resistance with bevacizumab and thalidomide
    Yang Min Ning
    DDOP OODP CDER, Food and Drug Administration, Silver Spring, MD, USA
    Clin Genitourin Cancer 7:E37-8. 2009
    ..The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study...
  88. ncbi request reprint Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins
    Sylvia S W Ng
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, and Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Res 64:821-4. 2004
    ..It is suggested that these agents may need to be used at much higher doses than anticipated for effective antiangiogenic chemotherapy...
  89. pmc Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
    James L Gulley
    Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 180:1432-7; discussion 1437. 2008
    ..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy...
  90. doi request reprint Pharmacogenetics of membrane transporters: a review of current approaches
    Tristan M Sissung
    Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Methods Mol Biol 448:41-62. 2008
    ..Finally, studies linking transporter genotype with clinical outcomes are discussed...
  91. doi request reprint Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
    Wilfred D Stein
    Medical Oncology Branch and Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:907-17. 2011
    ..We utilized a method estimating tumor growth and regression rate constants from serial PSA measurements, and assessed its potential in patients with metastatic castration resistant prostate carcinoma (mCRPC)...
  92. pmc Molecular alterations in primary prostate cancer after androgen ablation therapy
    Carolyn J M Best
    Pathogenetics Unit, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:6823-34. 2005
    ..The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent samples from primary and metastatic sites...
  93. ncbi request reprint Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
    Nicola F Smith
    National Cancer Institute, Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Expert Opin Drug Metab Toxicol 1:429-45. 2005
    ..Alteration of transporter function by either of these mechanisms may contribute to interindividual variability in drug disposition and response. In this review an update of this rapidly emerging field is provided...
  94. ncbi request reprint A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy
    James L Gulley
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 173:1567-71. 2005
    ..We present the largest published series of patients evaluating the timing of T and DHT increase after cessation of GnRH therapy...
  95. ncbi request reprint Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy
    Sylvia S W Ng
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 3:1212-3. 2004
    ..Thrombospondin-1, in turn, promotes endothelial cell apoptosis. It was also proposed that thrombospondin-1 levels might be used as a surrogate marker to monitor response to low-dose cyclophosphamide therapy in the clinic...
  96. pmc Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
    Tristan M Sissung
    Clinical Pharmacology Research Core, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    Eur J Cancer 42:2893-6. 2006
    ..This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics...
  97. ncbi request reprint Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
    David S Schrump
    Thoracic Oncology Section Surgery Branch, Cancer Therapy Evaluation Program, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:5777-85. 2006
    ..A phase I trial was done to examine pharmacokinetics, toxicities, and gene expression mediated by 5-aza-2'-deoxycytidine (DAC) in patients with thoracic malignancies...
  98. ncbi request reprint Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer
    McDonald K Horne
    Department of Laboratory Medicine, Hematology Service, W G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 23:315-8. 2003
    ..To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide...
  99. ncbi request reprint Mutations in the EGFR: the importance of genotyping
    Douglas K Price
    Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 3:434-5. 2004
    ..and Paez et al. help to explain those initial clinical findings. Both groups report that somatic mutations found within the coding region of the EGFR may predict the sensitivity to gefitinib treatment...